EA200100428A1 - Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты) - Google Patents

Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты)

Info

Publication number
EA200100428A1
EA200100428A1 EA200100428A EA200100428A EA200100428A1 EA 200100428 A1 EA200100428 A1 EA 200100428A1 EA 200100428 A EA200100428 A EA 200100428A EA 200100428 A EA200100428 A EA 200100428A EA 200100428 A1 EA200100428 A1 EA 200100428A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
optionally substituted
receptors
zero
dopamine
Prior art date
Application number
EA200100428A
Other languages
English (en)
Inventor
Майкл Стюарт Хэдли
Кристофер Норберт Джонсон
Грегор Джеймс Макдональд
Джеффри Стемп
Антонио Куок Кеонг Вонг
Original Assignee
Смитклайн Бичам Плс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9821976.9A external-priority patent/GB9821976D0/en
Priority claimed from GBGB9824340.5A external-priority patent/GB9824340D0/en
Priority claimed from GBGB9910711.2A external-priority patent/GB9910711D0/en
Priority claimed from GBGB9918032.5A external-priority patent/GB9918032D0/en
Application filed by Смитклайн Бичам Плс filed Critical Смитклайн Бичам Плс
Publication of EA200100428A1 publication Critical patent/EA200100428A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Соединения формулы (I), где Rпредставляет атом водорода или Cалкильную группу; q равно 1 или 2; A представляет группу формулы (a), (b), (c) или (d), где Ar представляет необязательно замещенное фенильное кольцо или необязательно замещенное 5- или 6-членное ароматическое гетероциклическое кольцо; или необязательно замещенную бициклическую кольцевую систему; Arи Ar, каждый независимо, представляет необязательно замещенное 5- или 6-членное ароматическое гетероциклическое кольцо; и Y представляет связь, -NHCO-, -CONH-, -CH- или -(CH)Y(CH)-, где Yпредставляет O, S, SOили CO, m и n каждый представляет ноль или 1, так что сумма m+n равна нулю или 1; при условии что, когда A представляет группу формулы (a), любой заместитель, присутствующий в Ar в орто-положении к карбоксамидному фрагменту, обязательно является водородом или метоксигруппой; r и s независимо представляют целое число от ноля до 3, так что сумма r и s равна целому числу от 1 до 4; V представляет связь, O или S; и их соли. Соединения формулы (I) и их соли обладают аффинностью к допаминовым рецепторам, в частности D3 рецепторам, и таким образом могут использоваться при лечении болезненных состояний, где модуляция D3 рецептора является выигрышной, например в качестве антипсихотических агентов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200100428A 1998-10-08 1999-10-06 Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты) EA200100428A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9821976.9A GB9821976D0 (en) 1998-10-08 1998-10-08 Compounds
GBGB9824340.5A GB9824340D0 (en) 1998-11-06 1998-11-06 Compounds
GBGB9910711.2A GB9910711D0 (en) 1999-05-07 1999-05-07 Compounds
GBGB9918032.5A GB9918032D0 (en) 1999-07-30 1999-07-30 Compounds
PCT/EP1999/007763 WO2000021951A1 (en) 1998-10-08 1999-10-06 Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)

Publications (1)

Publication Number Publication Date
EA200100428A1 true EA200100428A1 (ru) 2001-10-22

Family

ID=27451837

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100428A EA200100428A1 (ru) 1998-10-08 1999-10-06 Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты)

Country Status (30)

Country Link
US (1) US6605607B1 (ru)
EP (1) EP1119563B1 (ru)
JP (1) JP2002527433A (ru)
KR (1) KR20010085898A (ru)
CN (1) CN1329609A (ru)
AP (1) AP2001002114A0 (ru)
AR (1) AR023681A1 (ru)
AT (1) ATE316969T1 (ru)
AU (1) AU761018B2 (ru)
BG (1) BG105467A (ru)
BR (1) BR9914370A (ru)
CA (1) CA2346689A1 (ru)
CO (1) CO5140073A1 (ru)
CZ (1) CZ20011270A3 (ru)
DE (1) DE69929704T2 (ru)
EA (1) EA200100428A1 (ru)
ES (1) ES2255311T3 (ru)
HK (1) HK1038745A1 (ru)
HU (1) HUP0104280A3 (ru)
ID (1) ID28385A (ru)
IL (1) IL142388A0 (ru)
MA (1) MA26696A1 (ru)
NO (1) NO20011745L (ru)
NZ (1) NZ511018A (ru)
OA (1) OA11663A (ru)
PE (1) PE20001088A1 (ru)
PL (1) PL347237A1 (ru)
SK (1) SK4782001A3 (ru)
TR (1) TR200101025T2 (ru)
WO (1) WO2000021951A1 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
ATE316969T1 (de) 1998-10-08 2006-02-15 Smithkline Beecham Plc Tetrahydrobenzazepin-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
AU2001256733A1 (en) * 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
CZ20031311A3 (cs) 2000-11-14 2004-04-14 Smithkline Beecham P. L. C. Deriváty tetrahydroazepinu, užitečné jako modulátory receptorů dopaminu D3 (antipsychotická činidla)
WO2002051232A2 (en) * 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
EP1456178A1 (en) * 2001-12-21 2004-09-15 Smithkline Beecham Plc 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
US20050085461A1 (en) * 2002-02-13 2005-04-21 Cooper David G. Benzenesulfonamide derivatives
US7538121B2 (en) 2002-02-15 2009-05-26 Glaxo Group Limited Vanilloid receptor modulators
GB0224083D0 (en) * 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
CA2509413C (en) 2002-12-20 2012-05-01 Glaxo Group Limited Benzazepine derivatives for the treatment of neurological disorders
SI3632902T1 (sl) 2003-04-11 2022-01-31 Ptc Therapeutics, Inc. Spojina 1,2,4-oksadiazol benzojske kisline in njena uporaba za supresijo nesmiselne mutacije in zdravljenje bolezni
US20050137186A1 (en) 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
ATE529114T1 (de) 2003-12-18 2011-11-15 Abbott Gmbh & Co Kg Tetrahydrobenzazepine und ihre verwendung in der modulation des dopamin-d3-rezeptors
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
JP2007529511A (ja) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005094835A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1725240A4 (en) * 2004-03-17 2009-03-25 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
RU2008118422A (ru) * 2005-10-13 2009-11-20 Морфохем Акциенгезельшафт Фюр Комбинаторише Хеми (De) Производные 5-хинолина, обладающие антибактериальной активностью
PT3079688T (pt) * 2013-12-13 2018-02-28 Pf Medicament Derivado de cromona como um antagonista do receptor d3 de dopamina para seu uso para o tratamento de transtorno do espectro autista
KR102497273B1 (ko) 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
EP3368042A4 (en) 2015-10-30 2019-06-26 PTC Therapeutics, Inc. METHOD OF TREATING EPILEPSY
WO2018021447A1 (ja) * 2016-07-28 2018-02-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する含窒素縮環化合物
RS60209B1 (sr) 2017-03-20 2020-06-30 Forma Therapeutics Inc Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr)
CN111433201B (zh) * 2017-12-21 2022-05-27 江苏恒瑞医药股份有限公司 苯并氮杂䓬衍生物、其制备方法及其在医药上的应用
BR112020014875A2 (pt) * 2018-01-26 2020-12-08 Shionogi & Co., Ltd. Composto cíclico condensado tendo antagonismo de receptor de dopamina d3
CN110498768A (zh) * 2018-05-17 2019-11-26 上海中泽医药科技有限公司 庚嗪类化合物及其在制备抗精神分裂症药物中的应用
US20230055923A1 (en) 2018-09-19 2023-02-23 Forma Therapeutics, Inc. Activating pyruvate kinase r
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA792785B (en) 1978-07-07 1980-08-27 Smithkline Corp Mercapto substituted-2,3,4,5-tetrahydro-1h-3-benzazepines
US4220778A (en) 1978-10-30 1980-09-02 G. D. Searle & Co. 8-Aryl-1,2,3,4-tetrahydroisoquinoline and derivatives thereof
ZA816903B (en) 1980-10-17 1983-02-23 Pennwalt Corp N-(amino(or hydroxy)-1,2,3,4,-tetrahydroisoquinolines, precursors thereof, and methods of preparation
IL63918A0 (en) 1980-10-17 1981-12-31 Pennwalt Corp N-(amino(or hydroxy)phenethyl)-1,2,3,4-tetrahydroisoquinolines,their preparation and pharmaceutical compositions containing them
FR2618149B1 (fr) 1987-07-16 1989-09-22 Synthelabo Derives de n-aminoalkyl n-phenyl arylamides, leur preparation et leur application en therapeutique
IL89156A (en) 1988-07-12 1993-05-13 Synthelabo Derivatives of 2-((4-piperidinyl) methyl)- 1,2,3,4- tetrahydroisoquinoline, their preparation and their application in therapeutics
US5217977A (en) 1989-02-28 1993-06-08 Imperial Chemical Industries Plc Heterocyclic cycloalkanes
US5047406A (en) 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
US5633376A (en) 1990-12-28 1997-05-27 Neurogen Corporation Certain aminomethyl phenylimidazole derivatives; and 4-aryl substituted piperazinyl and piperidinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype ligands
US5681956A (en) 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
KR100220538B1 (ko) 1991-01-11 1999-09-15 뮈쉘 쥐르밀 아크리딘 유도체
US5466691A (en) 1991-08-09 1995-11-14 Yoshitomi Pharmaceutical Industries, Ltd. Thiophene compound
KR930703327A (ko) 1991-12-26 1993-11-29 고야 다다시 축합형 티오펜 화합물 및 그의 의약용도
US5532240A (en) 1991-12-26 1996-07-02 Yoshitomi Pharmaceutical Industries, Ltd. Condensed thiophene compound and pharmaceutical use thereof
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
ES2103479T3 (es) 1992-07-10 1997-09-16 Glaxo Lab Sa Derivados de anilida.
DE69321126D1 (de) 1992-08-06 1998-10-22 Smithkline Beecham Plc 5-(2-oxyphenyl)-pyrrol-derivate als dopamin-d3-rezeptor-antagonisten
US5294621A (en) 1992-10-07 1994-03-15 Ortho Pharmaceutical Corporation Thieno tetrahydropyridines useful as class III antiarrhythmic agents
GB9305644D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
GB9307400D0 (en) 1993-04-08 1993-06-02 Smithkline Beecham Plc Compounds
FR2706895A1 (en) 1993-06-22 1994-12-30 Synthelabo Tetrahydroisoquinoline derivatives, their preparation and their application in therapeutics
JP2959615B2 (ja) 1993-06-24 1999-10-06 吉富製薬株式会社 縮合型チオフェン化合物およびその医薬用途
JPH08511789A (ja) 1993-06-25 1996-12-10 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー フェニルピロール誘導体およびドーパミンｄ３拮抗薬としてのそれらの使用
GB9315801D0 (en) 1993-07-30 1993-09-15 Smithkline Beecham Plc Compounds
GB9315800D0 (en) 1993-07-30 1993-09-15 Smithkline Beecham Plc Compounds
IL110643A (en) 1993-08-12 1998-07-15 Astra Ab History of amidine, their preparation and the pharmaceutical preparations containing them
AU7665694A (en) 1993-09-21 1995-04-10 Yamanouchi Pharmaceutical Co., Ltd. N-(3-pyrrolidinyl)benzamide derivative
GB9320855D0 (en) 1993-10-09 1993-12-01 Smithkline Beecham Plc Compounds
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
GB9325827D0 (en) 1993-12-17 1994-02-23 Smithkline Beecham Plc Compounds
GB9402197D0 (en) 1994-02-04 1994-03-30 Smithkline Beecham Plc Compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9403199D0 (en) 1994-02-19 1994-04-13 Smithkline Beecham Plc Compounds
WO1995029891A1 (fr) 1994-04-28 1995-11-09 Yamanouchi Pharmaceutical Co., Ltd. Derive de n-(3-pyrrolidinyl)benzamide
US5414010A (en) 1994-05-10 1995-05-09 Warner-Lambert Company Dimeric benzimidazoles as central nervous system agents
DE4425145A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung von Thiazol- und Thiadiazolverbindungen
DE4425146A1 (de) 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
DE4425143A1 (de) 1994-07-15 1996-01-18 Basf Ag Substituierte Pyrimidinverbindungen und deren Verwendung
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
GB9418912D0 (en) 1994-09-20 1994-11-09 Fisons Corp Pharmaceutically active compounds
PL319511A1 (en) 1994-10-05 1997-08-18 Glaxo Wellcome Inc Parenteral pharmaceutic compositions containing gf120918a
US5478934A (en) 1994-11-23 1995-12-26 Yuan; Jun Certain 1-substituted aminomethyl imidazole and pyrrole derivatives: novel dopamine receptor subtype specific ligands
CA2205998C (en) 1994-11-23 2002-07-16 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
GB9426071D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9426090D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
EP0809641A1 (en) 1995-02-15 1997-12-03 Neurogen Corporation Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
EP0817767B1 (en) 1995-03-27 2000-05-24 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic agents
GB9512129D0 (en) 1995-06-15 1995-08-16 Smithkline Beecham Plc Compounds
AU6859096A (en) 1995-09-22 1997-04-09 Warner-Lambert Company Substituted cyclohexylamines as central nervous system agents
FR2741074B1 (fr) 1995-11-09 1997-12-19 Adir Nouveaux composes tetracycliques de la 1,4-oxazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
WO1997028166A1 (de) 1996-02-01 1997-08-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Thienochinoline
WO1997029079A1 (fr) 1996-02-06 1997-08-14 Japan Tobacco Inc. Composes chimiques et utilisation pharmaceutique
JPH09291034A (ja) 1996-02-27 1997-11-11 Yoshitomi Pharmaceut Ind Ltd 縮合ピリジン化合物およびその医薬としての用途
US5710274A (en) 1996-02-28 1998-01-20 Neurogen Corporation N-aminoalkyldibenzofurancarboxamides; new dopamine receptor subtype specific ligands
US5763609A (en) 1996-03-21 1998-06-09 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of gaba brain receptor ligands
US5703237A (en) 1996-04-18 1997-12-30 Neurogen Corporation N-Aminoalkyl-2-anthraquinonecarboxamides; new dopamine receptor subtype specific ligands
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
EP0917530B1 (en) 1996-05-11 2003-02-19 SmithKline Beecham plc Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
GB9612153D0 (en) 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
JP2000517301A (ja) * 1996-08-14 2000-12-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー テトラヒドロイソキノリン誘導体およびそれらの薬理学的使用
US6429212B1 (en) 1996-08-16 2002-08-06 Ishihara Sangyo Kaisha Ltd. Medicinal composition
YU23499A (sh) 1996-11-27 2001-07-10 Pfizer Inc. Inhibitorski amidi apo-b-sekrecije/mtp-a
FR2761985B1 (fr) 1997-04-10 1999-05-21 Adir Nouveaux composes amines du 6,7,8,9-tetrahydro-cyclopenta[a] naphtalene et du 2,3-dihydro-cyclopenta[e]indene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0979086A2 (en) 1997-04-28 2000-02-16 The University Of British Columbia Method and composition for modulating amyloidosis
GB9708694D0 (en) 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
HUP0003608A3 (en) * 1997-05-03 2001-06-28 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives, process for producing them and pharmaceutical compositions containing them
GB9709303D0 (en) 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
GB9710612D0 (en) 1997-05-23 1997-07-16 Glaxo Group Ltd Synthesis of acridine derivatives
DE19728996A1 (de) 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
GB9821977D0 (en) 1998-10-08 1998-12-02 Smithkline Beecham Plc Compounds
ATE316969T1 (de) 1998-10-08 2006-02-15 Smithkline Beecham Plc Tetrahydrobenzazepin-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
TWI274750B (en) 1999-01-12 2007-03-01 Abbott Gmbh & Co Kg Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
CN1329609A (zh) 2002-01-02
ID28385A (id) 2001-05-17
ES2255311T3 (es) 2006-06-16
PL347237A1 (en) 2002-03-25
AU1038100A (en) 2000-05-01
PE20001088A1 (es) 2000-12-02
OA11663A (en) 2004-12-08
HUP0104280A3 (en) 2002-07-29
KR20010085898A (ko) 2001-09-07
IL142388A0 (en) 2002-03-10
CO5140073A1 (es) 2002-03-22
BG105467A (en) 2001-11-30
EP1119563A1 (en) 2001-08-01
ATE316969T1 (de) 2006-02-15
SK4782001A3 (en) 2001-11-06
DE69929704T2 (de) 2006-07-20
EP1119563B1 (en) 2006-02-01
NO20011745D0 (no) 2001-04-06
JP2002527433A (ja) 2002-08-27
TR200101025T2 (tr) 2001-09-21
CA2346689A1 (en) 2000-04-20
HK1038745A1 (zh) 2002-03-28
NO20011745L (no) 2001-06-06
AU761018B2 (en) 2003-05-29
AR023681A1 (es) 2002-09-04
BR9914370A (pt) 2001-11-27
NZ511018A (en) 2003-09-26
HUP0104280A2 (hu) 2002-03-28
DE69929704D1 (de) 2006-04-13
US6605607B1 (en) 2003-08-12
CZ20011270A3 (cs) 2001-09-12
AP2001002114A0 (en) 2001-06-30
WO2000021951A1 (en) 2000-04-20
MA26696A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
EA200100428A1 (ru) Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты)
ES2188280T3 (es) Acetales heteroaril-ciclicos.
CO5070570A1 (es) DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE
DE69330351D1 (de) 5-arylindol-derivate und ihre verwendung als serotonin (5-ht1)-agonisten
AR014868A1 (es) UN COMPUESTO DERIVADO DE N,N ( SUSTITUIDO) FENIL (ARILO O HETEROARILO) PROPANAMINA, UNA COMPOSICIoN FARMACÉUTICA, USO DE DICHO COMPUESTO Y UN MÉTODO PARA PREPARARLO.
NO20015446L (no) Kinolin-derivater som inhibitorer for MEK-enzymer
EA200100310A1 (ru) Кислородсодержащие гетероциклические соединения
MX9602979A (es) Compuestos heterociclicos terapeuticos.
DK0677046T3 (da) Piperazinderivater som 5-HT-antagonister.
MY102744A (en) Aromatic derivatives, their preparation and thier use as antimicrobial agents.
HRP20031091B1 (en) Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
DE69928951D1 (de) 2,3-dihydro-1h-isoindol-derivate verwendbar als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel)
ES455909A1 (es) Procedimiento para preparar derivados de piperacina.
DE69512364T2 (de) Naphthalen-Derivate und ihre Verwendung als PGE- Agonisten und Antagonisten
ATE151750T1 (de) 3-(indol-3-yl) propensäurderivate, die als nmda- antagonisten nützlich sind
ATE215083T1 (de) Bicyclische carboxamide als 5-ht1a rezeptoren liganden
PT92494A (pt) Processo para a preparacao de novos derivados do indol
ES2186365T3 (es) Derivados de tetrahidroisoquinolina como moduladores de los receptores d3 de la dopamina.
ES2192342T3 (es) 2-(2,6-dioxo-3-fluoropiperidin-3-il)-isoindolinas sustituidas y su uso para reducir los niveles de tnfalfa.
TW351717B (en) Pyenyl-substituted cyclic ketoenols